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Pharmacogenomics in depression and 
antidepressants 
Brigitta Bondy, MD
Genetic factors are believed to play a major role in the
variation of treatment response and the incidence of
adverse effects to medication. The aim of pharmaco-
genetics is to elucidate this variability according to hered-
itary differences. Considering current hypotheses for the
mechanisms of action of antidepressants, most investiga-
tions to date have concentrated on mutations in genes
coding either for the pathways in the serotonergic and
noradrenergic systems or for drug-metabolizing enzymes.
Recent studies shifted the emphasis on the main mecha-
nism of drug action from changes in neurotransmitter
concentration or receptor function toward long-lasting
adaptive processes within the neurons. Although the
results are controversial, many studies support the hypoth-
esis that psychopharmacogenetics will help predict an
individual’s drug response, while minimizing the side
effects. The inclusion of functional genomics, which inves-
tigates the complex gene and/or protein expression in
response to a given drug, may lead to the development
of novel and safer drugs.   
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he first antidepressants (AD) were discovered
by chance almost 50 years ago.Despite recent advances
in the discovery and design of ADs,interindividual vari-
ability to treatment remains a serious problem in clinical
psychiatry. It is well known that there are large differ-
ences in dosage requirements and that,with a standard
dose of a given drug,a significant proportion of patients
do not respond satisfactorily while others suffer from
serious adverse effects.In both cases,patients do not ben-
efit from the full therapeutic efficacy and a switch
between different treatment regimens is often necessary
to find a more suitable alternative.
The variability in drug response is highly complex and can
be attributed to several physiological and environmen-
tal factors,such as the patient’s age,renal and liver func-
tion,nutritional status,smoking,alcohol consumption,and
physical activity (Figure 1).However,it has been recog-
nized for almost 50 years now that genetic factors also
influence both the efficacy of a drug and the likelihood of
adverse reactions.
1The concept of pharmacogenetics orig-
inated from clinical observations of patients with very
high or very low plasma drug concentrations when given
a fixed dose,and from the discovery that variations in the
DNA sequences of genes coding for metabolizing
enzymes are associated with these discrepancies.
The terms pharmacogenetics and pharmacogenomics are
closely related and often used interchangeably.However,
the terms do have distinct meanings.Pharmacogenetics
represents the variability in drug response and metabo-
lism due to genetic variants, while pharmacogenomics
involves the systematic investigation of the human
genome and alterations in complex gene and protein
expression over time in response to a given drug.There
are, however, many interactions between the two
Tapproaches and they complement each other at many
levels;therefore,the distinction is easily blurred.
2
Polymorphisms are investigated in genes coding for
either the pharmacokinetic pathways (encompassing the
processes that influence bioavailability) or pharmaco-
dynamic pathways (targets of drug action).The majority
of studies to date involve single genes or single
nucleotide polymorphisms (SNPs),but haplotype analy-
ses of several variants within one or more genes are gain-
ing importance.
3The overall aim of pharmacogenetics is
to contribute to drug choice and dosage according to the
individual genetic makeup, thus leading to a personal-
ized, more efficacious, and less harmful therapy. This
review will give a brief summary of the progress in the
field and assess the prospects for future success in this
area.
Polymorphic drug-metabolizing enzymes
All ADs are highly lipophilic compounds and,as such,sub-
ject to extensive metabolism by a number of enzymes,
including those of the cytochrome P-450 (CYP) family.The
CYPs were recognized quite as major source of pharma-
cokinetic variability,as they typically show large interindi-
vidual and sometimes intraindividual differences in activ-
ities due to genetic variants.More than 50 CYP genes have
been described in the human genome to date,but less than
10 of them are of major significance in psychiatry.Among
those are CYP 3A, which metabolizes about 50% of all
psychotropic drugs, followed by CYP 2D6, CYP 2C19,
CYP 1A2,and CYP 2C9.
4 CYPs show distinct but over-
lapping substrate specificities; their activities may be
induced or inhibited by certain drugs or foodstuffs,such as
grapefruit juice (an overview of the major CYPs,their AD
substrates, inhibitors, and inducers is given in Table I).
5
Thus,swallowing the drugs with juice or combining them
with other drugs (which is rather common in clinical psy-
chiatry) might have uncontrollable,interactive effects on
their bioavailability.
6
The presence of allelic variants in CYP enzymes with
varying degrees of functional significance may result in
three main phenotypes,poor metabolizers (PMs),normal
metabolizers (NMs),and extensive metabolizers (EMs).
The PMs lack an active form of the expressed enzyme
due to an inactivating allelic variant;NMs have at least
one copy of an active gene;and EMs contain duplicated
or amplified gene copies,thus leading to either increased
(maybe toxic) or decreased (maybe ineffective) concen-
trations of the drug.
7
CYP 2D6 is the most extensively studied P-450 isoen-
zyme in psychiatry. More than 70 allelic variants have
been identified so far,but only a few are clinically rele-
vant,eg,CYP 2D6*3A,CYP 2D6*4B,and CYP 2D6*5,
which all lead to the PM phenotype. Moreover, there
are considerable ethnic variations in the frequencies of
CYP 2D6 mutations, which are more common in
Caucasians (7%) and Africans (7% to 8%) than in the
Asian population (1%).
8 In contrast, the incidence of
PMs of CYP 2C19 substrates is much higher in Asians
(15% to 30%) than in Caucasians.
5 Several studies have
shown a significant contribution of the CYP 2D6 geno-
type on plasma concentrations of different ADs,
and PMs had a higher incidence of side effects.
9-11
Nevertheless,we should keep in mind that the involve-
ment of several different enzymes in the various meta-
bolic pathways may prevent large alterations in in vivo
clearance.
11Thus,CYP genotyping can be recommended
as a complement to plasma concentration determina-
tion when aberrant metabolic capacity is suspected.
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Selected abbreviations and acronyms
ACE angiotensin-converting enzyme
AD antidepressant
BDNF brain-derived neurotrophic factor





SNP single nucleotide polymorphism
SSRI selective serotonin reuptake inhibitor
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  • Receptors, transmitters
  • Signal transductionPharmacodynamic drug targets
ADs have a wide variety of targets within the neuro-
transmitter systems,ranging from neurotransmitter syn-
thesis,degrading enzymes,storage,receptors,and specific
transport proteins (Figure 2). Variations in DNA
sequences of these genes can alter the function or levels
of expression of neurotransmitters and enzymes and the
binding properties of receptors and transport proteins.
Newer concepts address signal transduction proteins and
other downstream protein polymorphisms.Most notably,
the superfamily of G-proteins,which have a key function
in signal transduction and are target proteins for more
than 50% of available drugs,is becoming a major goal of
investigation. Other downstream proteins, such as the
kinases or phosphatases, and proteins downstream to
transcription factors,and the expression of proteins are
target systems in pharmacogenetics and pharmaco-
genomics.
12 The proteins, which are related to synaptic
and neuronal plasticity have become special goals of
interest in terms of drug response.
13
Pharmacogenetic studies of ADs 
According to the pathophysiological mechanisms of affec-
tive disorders, which mainly postulate deficiency in
monoaminergic neurotransmission,ADs of various classes
affect the serotonin,norepinephrine,and dopamine path-
ways (Table II).
The serotonin transporter (5-HTT) is the initial target of
most ADs,especially the widely used selective serotonin
reuptake inhibitors (SSRIs).A functional variant was
identified in the promoter region of the 5-HTT gene with
an insertion/deletion of 44 bp,resulting in short (S) and
long (L) alleles.The S allele reduces the transcriptional
activity of the 5-HTT gene promoter,leading to reduced
5-HTT expression and 5-HT uptake.
14A number of case-
control association studies have outlined that individuals
carrying at least one L allele, respond more favorably
and rapidly to SSRIs,such as fluvoxamine and paroxe-
tine,
15 and the S/S genotype had been associated with
nonremission in citalopram and fluvoxamine treatment.
15
Taking all the findings together, the emerging picture
suggests a marked influence of the 5-HTT promoter
polymorphism on response to SSRIs in Caucasian popu-
lation.
16 However,opposite findings were reported in the
Asian population concerning the frequency of the L
allele and the response to treatment.The L allele fre-
quency in Asians was about one-third that in Caucasians,
and persons with the S/S genotype responded more
favorably to treatment.
These conflicting results are puzzling,but suggest that dif-
ferential interactions in different populations exist,
maybe via interaction with other functional gene variants
(for a review,see reference 16).Interestingly,the 5-HTT
variants are not only important for treatment with the
SSRIs, but also for those with other compounds, eg,
lithium,which is widely used as mood stabilizer.Serretti
and colleagues have shown that patients with the L/L or
L/S genotype have a better outcome than those with the
S/S variant.
17
Current concepts: signal transduction pathways,
neuronal plasticity, and stress response
Our present knowledge about the pathophysiological basis
of depression and the mechanisms of psychotropic drug
action has increased during the last few years.There has
therefore been some shift in emphasis from the focus on
metabolizing enzymes, neurotransmitter receptors, and
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Table I. Major cytochrome P450 isoenyzmes (CYP), their antidpressant (AD) substrates, enzyme inhibitors, and inducers.
5 TCA, tricyclic AD; SSRI,
selective serotonin reuptake inhibitor.
Enzyme Substrate Inhibitor Inducer
CYP 1A2 TCAs, fluvoxamine, mirtazapine Fluvoxamine, grapefruit juice Carbamazepine, hyperforate, nicotine
CYP 2D6 TCAs, SSRIs, mirtazapine,  Fluoxetine, fluvoxamine, Not known
venlafaxine, sertraline moclobemide, propranolol
CYP 2C9 Amitriptyline, fluoxetine, phenytoin Fluvoxamine Modafinil
CYP 2C19 TCAs, citalopram, moclobemide,  Fluoxetine, valproic acid,  Modafinil
venlafaxine, etc fluvoxamine
CYP 3A4 TCAs, fluoxetine, mirtazapine,  Fluoxetine, fluvoxamine,  Hyperforate, modafinil, phenytoin
reboxetine, venlafaxine, etc grapefruit juicetransporters toward long-lasting adaptive processes,which
are related to alterations in signal transduction pathways
and mechanisms involving neuronal plasticity, or result
from a response to environmental stressors (Figure 2).
The majority of studies concerning signal transduction path-
ways were carried out on polymorphisms within G-proteins,
the key elements of intracellular pathway regulation by
transmission of signals from receptors to effector proteins.
We have investigated a functional polymorphism on the β3
subunit of the G-protein (C825T), which was shown to
increase signal transduction,
18 and found an association of
the T/T homozygosity to treatment response of ADs.
19 Our
results were replicated in two further studies,which showed
that patients with the Gβ3 T/T variant responded better to
AD treatment and that this effect was independent of the
analyzed demographic and clinical variables.
20,21This find-
ing highlights the possible influence of downstream mes-
senger systems in treatment-mediated responses and may
facilitate the identification of novel key targets that may
also be relevant in the etiology of depression.
Secondary signaling mechanisms downstream from the
receptors and G-proteins, such as cyclic adenosine
monophosphate (cAMP), phosphodiesterase, cAMP
response element, and cAMP binding proteins are cur-
rently under investigation,but only a marginal association
has been found so far.
22
In recent years,it has become obvious that chronic treat-
ment with ADs influences the gene expression of poten-
tial target genes,eg,neurotrophic factors (brain-derived
neurotrophic factor [BDNF]), its receptor (trkB), and
vesicle proteins (synapsin I-III,synaptophysin).These pro-
teins are involved in neuronal or synaptic plasticity mech-
anisms and the transcription factor CREB (cAMP
response element binding protein) represents the link
between the observed short- and long-term treatment
effects (Figure 2).
23 In postmortem studies,an increase of
BDNF and trkB levels were found in depressive patients
who were receiving AD treatment at the time of death.
24
Moreover,the serum levels of BDNF were also decreased
in untreated patients and showed a correlation with the
severity of symptoms.
25 BDNF has not only been associ-
ated with affective disorders;it also seems to be essential
in mediating the neuroprotective effect of lithium and has
been implicated in the mode of action of antipsychotics.
26
However,pharmacogenetic studies with polymorphisms
in the BDNF gene were thus far inconclusive.
It has been postulated that decreased BDNF seen in
depressed patients may be secondary to increased cortisol
levels,a phenomenon which has been repeatedly described
in alterations of stress-hormone regulation in affective dis-
orders.Hyperactivity of the hypothalamo-pituitary adrenal
(HPA) axis with elevated secretion of corticotrophin-releas-
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Figure 2. Signal transduction cascade: potential candidate genes for
mechanisms of antidepressant action. NE, norepinephrine; 5-HT,
5-hydroxytryptamine (serotonin); R, G-protein–coupled recep-
tor; Gαβγ, G-protein–αβγ complex; AC, adenylylcyclase; PLC,
phospholipase C; cAMP, cyclic adenosine monophosphate;
PKA/PKC, protein kinase A/C; pCREB, phosphorylated cAMP

















Gαβγ Gαβγing factor (CRF), and subsequently cortisol, as well as
decreased glucocorticoid receptor sensitivity and disturbed
feedback mechanisms are well known.
27 In this context,our
own results from two independent clinical studies from a
cooperation with the Max Planck Institute for Psychiatry in
Munich are of importance.To investigate a possible associ-
ation between genes regulating HPA axis and response to
ADs and susceptibility for depression,we genotyped SNPs
in genes regulating the HPA axis activity in depressed
patients and matched controls.We found significant asso-
ciations between the response to ADs and SNPs in the
FKBP5 gene,a glucocorticoid receptor (GR)–regulating
cochaperone of hsp-90 in two independent samples.
Patients homozygous for the minor allele of the associated
SNPs responded almost 2 weeks faster to AD drug treat-
ment than patients with the other genotypes.
28
Disturbances of the HPA axis are also mirrored by genetic
findings in the angiotensin-converting-enzyme (ACE)
gene.ACE is not only involved in blood pressure regula-
tion,but is also highly expressed within the central nervous
system (CNS), where its primary function comprises
degradation of neuropeptides,including bradykinin and
substance P.ACE is further supposed to modulate the reg-
ulation of the HPA axis,thereby interacting with synthe-
sis and production of neuroactive steroids.
29
Within our own studies,we could show that the Dallele of
a functional insertion/deletion (I/D) polymorphism (the D
allele is associated with higher ACE levels and higher neu-
ropeptide degradation capabilities) was associated with
several methods of AD treatment,including pharmaco-
logical treatment,electroconvulsive treatment (ECT),tran-
scranial magnetic stimulation (TMS),and sleep depriva-
tion.
30,31 Moreover,we observed a relationship between the
Dallele and the hyperactivity of the HPA axis,determined
by the combined dexamethasone/corticotropin-releasing
hormone test.
32 Our findings concerning the ACE gene
may have a great impact, not only as a missing link
between affective disorders and cardiovascular diseases,
33
but also due to a probable function of the ACE gene as a
signal transduction component.A recent study has demon-
strated that the expression of ACE and other target genes
is enhanced by ACE-associated kinases and, therefore,
ACE might have an influence on signal transduction
mechanisms in the CNS and the periphery.
34
Future aspects: from pharmacogenetics 
to pharmacogenomics
Although the above findings in the field of pharmaco-
genetics are important,none of the positive results can
fully account for the heterogeneity in response to AD
treatment. Moreover, due to the complexity of drug
response, single mutations in one gene are unlikely to
cause the continuous variability in response.
The pharmacogenomic approach uses recent advances in
experimental genomics and proteomics (the investigation
of all the proteins in a cell or organism),together with the
available sequence information of the Human Genome
Project. These developments will not only enable
genome-wide screens of several millions of SNPs with-
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Table II. Pharmacogenetics of antidepressant drugs and candidate genes. SERT, serotonin transporter; 5-HT2A, serotonin receptor 2A; TPH1, tryptophan
hydroxylase 1; Gβ3, G-protein β3 subunit; NET, norepinephrine transporter; MAO-A, monoamine oxidase A; DRD2, dopamine D2 receptor;
DRD3, D3 receptor; DRD4, dopamine D4 receptor; ACE, angiotensin-converting enzyme; BDNF, brain-derived neurotrophic factor; FKBP5: FK506
binding protein 5.
Gene Polymorphism Finding
SERT 44 bp ins/del Response to SSRIs (fluoxetine, fluvoxamine, citalopram, paroxetine)
5-HT2A T102C, C-1420T, G-1438A No association
TPH1 A218C C/C associated with better response to fluvoxamine, paroxetine
G 3 C825T T/T associated with better response
NET T-182C; G-1287A No association
MAO-A 30 bp repeat No association
DRD2 Ser311Cys No association
DRD3 Ser9Gly No association
DRD4 48 bp repeats No association
ACE ins/del Discrepant results
BDNF Val166Met No association
FKBP5 rs1360780 (C/T) TT associated with better responseout the use of specific hypotheses and a candidate gene
strategy,but also functional investigations of gene and/or
protein expression over the whole genome or proteome.
35
Although most of the data available so far derived from
animal studies,the finding of Landgrebe et al,
36 who per-
formed a gene expression analysis in mice treated with
paroxetine and mirtazapine,is remarkable.The authors
found that both drugs led to a downregulation of four
common genes,thus suggesting that ADs with different
pharmacological principles of action can share the same
molecular targets even through the primary pathways on
which they act are different.This finding underlines the
recent hypothesis that the initial mechanisms of action
trigger subsequent events in the signal transduction cas-
cade and,finally,protein expression.
Although all the above results have to be replicated and
validated in further experiments and also analyzed in
vivo,there is no doubt that large-scale gene and/or pro-
tein expression analysis will be performed in the near
future in many laboratories by using all these rapidly
growing technologies of functional genomics. The
expected results will provide new insights in the patho-
physiology of psychiatric disorders.Such detailed knowl-
edge will have profound effects on the diagnosis, pre-
vention,and treatment of these diseases.
Conclusion
Although many investigations have shown that genetic
variations in target proteins influence their interaction
with ADs,the results are still not conclusive and far from
the original concept of tailoring the drug regimen to an
individual’s predisposition and predicting a patient’s
response to therapeutic agents.We have to be aware that
the phenotype of drug response is highly complex,rep-
resenting a classical example of the outcome of
gene–gene or gene–environment interactions.Thus,sin-
gle mutations are unlikely to cause the continuous vari-
ability observed in response to psychiatric treatment.
Moreover, clinical factors can be problematic, as they
include the confounding variable of placebo response,
the issue of inadequate sample sizes,the study of differ-
ent drug-response phenotypes and patient populations,
as well as the use of continual versus categorical out-
come measures.Two key elements are needed to per-
form valid pharmacogenomic studies: explicit and con-
sistent definition of drug-response phenotype and
knowledge of polymorphic candidate genes with rele-
vance to the mechanism of drug action.Nevertheless,the
field of pharmacogenetics and pharmacogenomics is
expanding rapidly, the development of new, fast, and
cost-effective methods for the investigation of the indi-
vidual genetic/genomic profile is under way, and the
incorporation of novel research areas, such as pharma-
coproteomics,will lead to better insights into disease and
treatment processes.The identification of novel drug tar-
gets and the determination of patient subpopulations are
ambitious methods that may help individualize phar-
macological therapy in psychiatry. ❏
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